Immunic Therapeutics
Immunology & Inflammation Therapeutics
15Open roles8 posted in 30 days+4 this week
$270kMedian advertised pay$210k – $270k+13% vs market
Facts
as of Nov 15, 2026Immunic is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases.
It is hiring: 15 open roles, 8 of them posted in the last 30 days. Its stated pay is 13% above the market estimate for the same roles.
- Founded
- 2016
- Open roles
- 15 in 2 citiesAlion job postings
- Official records
- Wikidata Q135319663
- Website
- imux.com
As of Nov 15, 2026, Alion lists 15 open roles at Immunic Therapeutics. It was founded in 2016. The median pay stated in its open roles is $270k, across 12 postings that state pay.
Sources: company registers, GLEIF, Wikidata, the company's site, Alion job postingsReport a mistake
What the registers and the postings say about this employer.
Sanctions lists
OFAC SDN, EU consolidated
No match
Phishing reports
OpenPhish, Phishing.Database
None
Layoff notices
US WARN notices on file
None
Full employer checkScam signs in adverts, mail records, visa registers, domain history
Sources: company registers, the Alion truth index, OFAC and EU sanctions lists, US WARN notices
Hiring
All open roles →Hiring at full speed: most open roles are fresh.
Biotech is the largest family, 25 of open roles.
8Posted in 30 days53% of open roles are fresh
100%Remote roles15 of 15
1Roles in AI7% of open roles
2Hiring offices
Can they hire you from United States?by your location
Likely
1 open roles are in your country: you apply locally, no move needed.
No posting offers visa sponsorship. Remote roles: 15.
Alion signals0-100
Demand32
Pay56
Your chance48
How badly they need people, whether they pay, how realistic getting in is.
Where the openings areshare of open roles · trend
What postings ask forlanguages named in open roles
Degree asked
Bachelor's Degree 69%Master's Degree 15%Doctoral Degree (PhD) 15%
Experience asked: 9.3 years on average, in 14 postings. 13 postings state a degree.
Contract type
Full-Time 15
Visa sponsorship: none statedRelocation: none stated
Source: the company's careers site, read by Alion several times a day; market medians from all open roles of the same family
Pays 13% above the market estimate for the same roles.
$270kMedianmarket estimate $238k
$210k – $270kTypical rangeUSD a year
$410kHighest paying roleVice President, Pharmacovigilance
Pay by levelmiddle half of stated pay, median marked · dashed: market median $238k
$0$75k$150k$225k$300k
Source: the pay stated in the company's postings, normalised to USD a year
Footprint
Hiring in 2 cities in 2 countries.
2Cities
2Countries
BostonBusiest site
Loading the map
| Site | Type | Open roles | Hires most for | Engineering |
|---|---|---|---|---|
| Boston United States | Remote hub | 8 | Sales, Biotech, Leadership | 0% |
| Gräfelfing Germany | Corporate office | 3 | Finance, HR, Biotech | 0% |
Source: office addresses in postings and company registers
Peers
Compare →Ranked #3 by open roles among its 11 closest peers.
| # | Company | HQ | Open roles | Size | |
|---|---|---|---|---|---|
| 1 | Nurix Therapeutics | San Francisco, United States | 24 | 201-500 | |
| 2 | DBV Technologies | Washington, United States | 16 | ||
| 3 | Immunic Therapeutics | Boston, United States | 15 | ||
| 4 | Vera Therapeutics | Brisbane, United States | 10 | 51-200 | |
| 5 | Oruka Therapeutics | Waltham, United States | 10 | 51-200 | |
| 6 | SEISMIC TX | Watertown, United States | 6 | 201-500 | |
| 7 | Climb Bio | Boston, United States | 5 | 51-200 | |
| 8 | Dianthus Therapeutics | New York, United States | 5 | 201-500 |
Source: Alion's similar-companies engine (industry segments, technologies, headquarters country, size)
Financials
1 public grant on record, $706k in total.
$706kPublic grants1 public grant
Money by yearUSD, rounds and grants
Largest rounds and grants
2019
$706k
Sources: funding announcements, grant and company registers
Tech stack
Full chapter →Technologies named in job postings at Immunic Therapeutics over the last 12 months, by layer, with the share of postings for each.
11Technologies in use
9Postings analysed
61/100Stack modernityAI adopter
Sign in to see how your skills match this stackSign In
Full Immunic Therapeutics tech stack11 technologies · by team · pay by technology · changes · similar stacks
Source: the technologies named in the company's postings and on its site
Milestones
Each milestone is dated by its source: registers, filings, the press
Newsroom
Oct 72026
Blog
- Four Accepted Abstracts Further Characterize Investigational Vidofludimus Calcium's Profile in Multiple Sclerosis Across Long-Term Disability Outcomes, EBV-Related Immune Activ…
Sep 292026
Blog
NEW YORK, September 29, 2026 - Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today…
Sep 22026
Blog
NEW YORK, September 2, 2026 - Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today a…
Sep 12026
Blog
- New C-Suite Role and Appointment Underscore Commitment to Building a Strong, Commercial-Ready Data Ecosystem, in Preparation for Potential NDA Submission and Commercialization…
Aug 112026
Blog
- Leadership Team Expanded with Key Executive Appointments, Including Chief Executive Officer, Chief Medical Officer and Chair of the Board of Directors, to Support Clinical Deve…
Aug 102026
Blog
- Appointment Strengthens Board with Financial, Capital Markets and Commercial Leadership Expertise as the Company Approaches Pivotal Phase 3 ENSURE Readout in Relapsing Multiple…
Sources: the outlets named on each headline, each story once